174 related articles for article (PubMed ID: 31846038)
1. Expression of FOXP3 in Canine Gliomas: Immunohistochemical Study of Tumor-Infiltrating Regulatory Lymphocytes.
Pi Castro D; José-López R; Fernández Flores F; Rabanal Prados RM; Mandara MT; Arús C; Pumarola Batlle M
J Neuropathol Exp Neurol; 2020 Feb; 79(2):184-193. PubMed ID: 31846038
[TBL] [Abstract][Full Text] [Related]
2. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
[TBL] [Abstract][Full Text] [Related]
3. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
[TBL] [Abstract][Full Text] [Related]
5. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
6. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.
Han S; Zhang C; Li Q; Dong J; Liu Y; Huang Y; Jiang T; Wu A
Br J Cancer; 2014 May; 110(10):2560-8. PubMed ID: 24691423
[TBL] [Abstract][Full Text] [Related]
7. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of immune cell infiltration in canine gliomas.
Krane GA; O'Dea CA; Malarkey DE; Miller AD; Miller CR; Tokarz DA; Jensen HL; Janardhan KS; Shockley KR; Flagler N; Rainess BA; Mariani CL
Vet Pathol; 2021 Sep; 58(5):952-963. PubMed ID: 34196247
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
10. Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: Spatial distribution and score as relevant features of tumor malignancy.
Muscatello LV; Avallone G; Brunetti B; Bacci B; Foschini MP; Sarli G
Vet J; 2022; 283-284():105833. PubMed ID: 35489672
[TBL] [Abstract][Full Text] [Related]
11. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic Differences in Tumor-Infiltrating Lymphocytes and Neovascularization Between Primary Cutaneous Melanoma With and Without Metastasis: An Immunohistochemical Study of 80 Cases.
Salgüero I; Roustán G; Requena L; Suárez D; García-Fresnadillo D; Redondo JI; Nájera L
Am J Dermatopathol; 2021 Nov; 43(11):811-818. PubMed ID: 33534211
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma.
Yue Q; Zhang X; Ye HX; Wang Y; Du ZG; Yao Y; Mao Y
J Neurooncol; 2014 Jan; 116(2):251-9. PubMed ID: 24276989
[TBL] [Abstract][Full Text] [Related]
14. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
[TBL] [Abstract][Full Text] [Related]
15. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
16. Quantification of CD3, FoxP3, and granzyme B immunostaining in canine renal cell carcinoma.
Cournoyer A; Amerman H; Assenmacher CA; Durham A; Perry JA; Gedney A; Keuler N; Atherton MJ; Lenz JA
Vet Immunol Immunopathol; 2024 May; 271():110741. PubMed ID: 38520894
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes in canine melanocytic tumours: An investigation on the prognostic role of CD3
Porcellato I; Silvestri S; Menchetti L; Recupero F; Mechelli L; Sforna M; Iussich S; Bongiovanni L; Lepri E; Brachelente C
Vet Comp Oncol; 2020 Sep; 18(3):370-380. PubMed ID: 31750993
[TBL] [Abstract][Full Text] [Related]
18. Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma.
Al-Qahtani D; Anil S; Rajendran R
J Oral Pathol Med; 2011 Sep; 40(8):636-42. PubMed ID: 21352381
[TBL] [Abstract][Full Text] [Related]
19. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
20. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
